ANPC
Income statement / Annual
Last year (2022), AnPac Bio-Medical Science Co., Ltd.'s total revenue was $12.04 M,
a decrease of 33.04% from the previous year.
In 2022, AnPac Bio-Medical Science Co., Ltd.'s net income was -$103.60 M.
See AnPac Bio-Medical Science Co., Ltd.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$12.04 M |
$17.99 M |
$20.51 M |
$10.85 M |
$10.25 M |
$5.69 M |
Cost of Revenue |
$3.71 M
|
$5.73 M
|
$7.63 M
|
$6.05 M
|
$5.67 M
|
$3.95 M
|
Gross Profit |
$8.34 M
|
$12.25 M
|
$12.88 M
|
$4.80 M
|
$4.58 M
|
$1.73 M
|
Gross Profit Ratio |
0.69
|
0.68
|
0.63
|
0.44
|
0.45
|
0.3
|
Research and Development Expenses |
$9.53 M
|
$16.20 M
|
$11.58 M
|
$9.84 M
|
$10.11 M
|
$11.41 M
|
General & Administrative Expenses |
$70.79 M
|
$80.68 M
|
$74.76 M
|
$70.78 M
|
$28.85 M
|
$24.94 M
|
Selling & Marketing Expenses |
$12.15 M
|
$21.42 M
|
$19.67 M
|
$13.63 M
|
$9.83 M
|
$6.49 M
|
Selling, General & Administrative Expenses |
$82.94 M
|
$102.10 M
|
$94.43 M
|
$84.41 M
|
$38.67 M
|
$31.43 M
|
Other Expenses |
$0.00
|
-$8.08 M
|
$15.73 M
|
-$373,000.00
|
-$593,000.00
|
-$178,000.00
|
Operating Expenses |
$92.47 M
|
$118.30 M
|
$106.01 M
|
$93.88 M
|
$48.19 M
|
$42.66 M
|
Cost And Expenses |
$96.18 M
|
$124.03 M
|
$113.64 M
|
$99.93 M
|
$53.86 M
|
$46.61 M
|
Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$373,000.00
|
$4.26 M
|
$1.14 M
|
$2.61 M
|
$925,000.00
|
$338,000.00
|
Depreciation & Amortization |
$5.74 M
|
-$4.04 M
|
$15.71 M
|
-$4.27 M
|
$3.14 M
|
$2.29 M
|
EBITDA |
-$78.40 M |
-$112.10 M |
-$77.41 M |
-$93.35 M |
-$38.19 M |
-$36.44 M |
EBITDA Ratio |
-6.51
|
-6.12
|
-3.77
|
-8.61
|
-3.73
|
-6.41
|
Operating Income Ratio |
-6.99
|
-5.9
|
-4.54
|
-8.21
|
-4.25
|
-7.2
|
Total Other Income/Expenses Net |
-$21.59 M
|
-$9.17 M
|
$13.90 M
|
-$12.76 M
|
$1.11 M
|
$1.61 M
|
Income Before Tax |
-$105.73 M
|
-$121.27 M
|
-$80.65 M
|
-$101.84 M
|
-$42.50 M
|
-$39.31 M
|
Income Before Tax Ratio |
-8.78
|
-6.74
|
-3.93
|
-9.39
|
-4.15
|
-6.91
|
Income Tax Expense |
-$2.13 M
|
-$1.18 M
|
-$88,000.00
|
-$218,000.00
|
-$199,000.00
|
$9,000.00
|
Net Income |
-$103.60 M
|
-$120.09 M
|
-$80.57 M
|
-$101.62 M
|
-$42.06 M
|
-$39.08 M
|
Net Income Ratio |
-8.6
|
-6.68
|
-3.93
|
-9.37
|
-4.1
|
-6.87
|
EPS |
-54.18 |
-176.53 |
-143.99 |
-205.96 |
-3.76 |
-3.49 |
EPS Diluted |
-54.18 |
-176.53 |
-143.99 |
-205.96 |
-3.76 |
-3.49 |
Weighted Average Shares Out |
$1.91 M
|
$680,276.00
|
$559,504.00
|
$493,400.00
|
$11.20 M
|
$11.20 M
|
Weighted Average Shares Out Diluted |
$1.91 M
|
$680,276.00
|
$559,504.00
|
$493,400.00
|
$11.20 M
|
$11.20 M
|
Link |
|
|
|
|
|
|